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ABSTRACT
The epidemic of intrauterine growth restriction (IUGR) continues to be 
a leading cause of perinatal morbidity and mortality throughout the 
world. This condition has been linked to the development of metabolic 
health problems such as obesity, hypertension, glucose intolerance, 
and type 2 diabetes at all ages. Previous studies have demonstrated 
that IUGR fetal adaptations impair proper glucose homeostasis in part 
via changes in insulin responsiveness in key tissues including skeletal 
muscle and liver, and that these deficits persists into adulthood. Many 
components of insulin signaling pathways associated with glucose 
metabolic regulation have been evaluated in IUGR tissues for adaptive 
changes. Among these are mammalian target of rapamycin complexes 
1 and 2 (mTORC1/2) and their associated pathways, which function 
in mitochondrial control and maintenance. However, recent findings 
demonstrate that β
2
 adrenoceptors (β
2
AR) appear to activate an insulin-
independent pathway or pathways that modify glucose metabolism via 
mTORC1/2 complexes. These findings represent a novel potential target 
for interventions that could improve the treatment and prevention of 
IUGR-induced metabolic disorders. This review will focus on mechanistic 
components of β
2
AR-mTORC1/2 signaling as well as their role in 
regulating glucose oxidative metabolism within skeletal muscle.
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INTRODUCTION
Intrauterine growth restriction (IUGR) is charac-
terized by developmental adaptations to chronic 
fetal malnutrition that result in asymmetric 
growth restriction of skeletal muscle and other 
non-visceral soft tissues, regardless of birth weight 
percentile (Yates et al., 2012). Indeed, asymmet-
ric growth demarcates this condition from other 
non-nutritional causes of small-for-gestational-age 
newborns (Sharma et al., 2016). Worldwide, IUGR 
affects approximately 30 million pregnancies 
each year and the incidence is six-fold greater 
in developing countries, well above the interna-
tionally-recommended level for initiating public 
health actions (de Onis et al., 1998). Studies in 
animal models demonstrate that IUGR is a major 
predisposing factor for a multitude of postnatal 
metabolic complications related to impaired insu-
lin sensitivity and glucose homeostasis (Camacho 
et al., 2017). Studies by us and others have demon-
strated the ability of β2 adrenoceptors (β2AR) to 
regulate glucose metabolism in skeletal muscle 
via insulin-independent pathways (Cadaret et al., 
2017; Mukaida et al., 2017; Cipolletta et al., 2017). 
Furthermore, Yates et al. (2011) highlighted the 
ability of fetal catecholamines to mediate metabolic 
adaptations in ovine models of IUGR. Together, 
these findings demonstrate the need for a better 
understanding of how chronic adrenergic stimula-
tion contributes to the development and progres-
sion of IUGR. Recent work in our lab demonstrates 
that acute β2 stimulation also acts synergistically 
with insulin to enhance stimulation of glucose 
oxidation in mature skeletal muscle (Cadaret et al., 
2017). In stark contrast, however, fetal adaptations 
to chronically increased catecholamines impair 
skeletal muscle insulin responsiveness and reduce 
glucose oxidation rates in IUGR fetal and postnatal 
muscle (Limesand et al., 2007; Brown et al., 2015; 
Camacho et al., 2017). These results demonstrate 
that β2-adrenergic and insulin activity can lead to 
similar downstream effects on glucose metabolism 
via distinctly different pathways that ultimately 
converge downstream. One likely site of conver-
gence is the activation of mTORC1 and mTORC2, 
which appear to be common downstream targets 
for both pathways, as illustrated in Figure 1. Both 
mTORC1 and mTORC2 are potent regulators of 
glucose uptake when activated by the insulin/
PI3K/PDK1 pathway or inhibited by stress-acti-
vated AMPK and TSC pathways (Polak & Hall, 
2009). Previous findings indicate that mTORC1/2 
also influence mitochondrial oxidation rates and 
are activated by insulin-independent increases in 
cyclic AMP (cAMP) activity (Cunningham et al., 
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2007; Schieke et al., 2006). Adrenergic regulation of 
skeletal muscle and its crosstalk with insulin may 
represent novel therapeutic targets for improving 
metabolic outcomes in IUGR affected individuals. 
In this review, we discuss how these findings relate 
to our recent studies, which demonstrate that β2 
adrenergic stimulation increases both basal and 
insulin-stimulated glucose oxidation rates in skele-
tal muscle without concurrently increasing glucose 
uptake (Cadaret et al., 2017; Merrick et al., 2017). 
β2 adrenergic activation of mTORC2
β2 adrenoceptors are G protein-coupled receptors 
that primarily activate adenylyl cyclase to increase 
production of the second messenger cAMP 
(Mukaida et al., 2017). Greater concentrations of 
cAMP produced by β2 stimulation lead to activation 
of mTORC2 by phosphokinase A (PKA)-mediated 
phosphorylation at Ser2481 (Sato et al., 2014).  In 
turn, mTORC2 then activates Akt via Ser473 phos-
phorylation (Sato et al., 2014). Not surprisingly, 
inhibition of mTORC2 activity leads to decreased 
phosphorylation of Akt and a reduction in the 
associated downstream effects (Kline et al., 2006; 
Sarbassov et al., 2005). This pathway is significant 
because it represents a route of Akt activation that 
does not require the involvement of PI3K/PDK1, 
which activates Akt via phosphorylation at Thr308 
(Sato et al., 2014), and demonstrates one potential 
mechanism by which β2 adrenergic-mediated path-
ways lead to the activation of Akt in an insulin-in-
dependent manner. Additional comparative studies 
demonstrate that inhibition of Akt leads to the loss 
of both insulin-mediated and β2 agonist-mediated 
effects (Mukaida et al. 2017). This further indicates 
that these pathways differ upstream, presumably 
at the level of mTORC2, but ultimately converge 
at Akt activation. Convergence of the β2/cAMP/
mTORC-mediated pathway with the insulin-PI3K 
pathway in skeletal muscle may explain the addi-
tive effects of insulin and β2 stimulation on glucose 
oxidation by our lab and others (Cadaret et al., 
2017; Scheidegger et al., 1984). These findings also 
indicate that mTORC1 is a downstream mediator 
of the effects of β2 adrenoceptor activation, as it 
is responsive to both Akt and cAMP (Kline et al., 
2006; Kim et al., 2010).
Differential pathways of β2-stimulated 
mTORC1 activation
Past studies have shown that Akt and its substrate 
PRAS40 are important activators of mTORC1 in 
skeletal muscle (Kline et al., 2006; Oshiro et al., 
2007). A subsequent study by Kim et al. (2010) also 
demonstrated cAMP to be an indirect promoter 
of mTORC1 activity via its inhibitory action on 
PDE4D, a known suppressor of mTORC1. These 
parallel pathways (summarized in Figure 1) repre-
sent a multi-faceted capacity for β2 adrenergic regu-
lation of mTORC1 via Akt (similarly to insulin), 
as well as via a unique Akt-independent PDE4D-
mediated pathway. Ultimately, each of these path-
ways is capable of upregulating activity of the small 
GTPase, Rheb, which is a well-characterized acti-
vator of mTORC1 (Kim et al., 2010; Oshiro et al., 
2007; Polak and Hall, 2009). Indeed, these findings 
would appear to indicate that the two pathways 
re-converge upon activating their common hub, 
Rheb. Moreover, these parallel pathways offer a 
likely explain for how β2 adrenergic stimulation 
acts both with and independently of insulin in 
regulating skeletal muscle mTORC1 activity and 
subsequent glucose oxidation.
mTORC1 mediates mitochondrial oxidative 
function
Studies have demonstrated that mTORC1 is a 
central metabolic regulator capable of eliciting 
rapid changes in cellular metabolism (Cunningham 
et al., 2007; Ramanathan and Schreiber, 2009). 
Indeed, inhibition of mTORC1 decreases mito-
chondrial respiration rates in an S6K1/4eBP1-
independent manner (Ramanathan & Schreiber, 
2009). This non-canonical pathway functions via 
post-transcriptional co-activation of YY1 and 
PGC-1α, which are transcription factors integral 
to the control of mitochondrial oxidative metab-
olism (Cunningham et al., 2007). It is noteworthy 
that the effects on mitochondrial function were not 
due to changes in overall mitochondrial content in 
either of the above studies, further implicating the 
acute effects of this pathway. Interestingly, Polak 
& Hall (2009) have described how tissue-specific 
loss of mTORC1 results in similar phenotypic traits 
and metabolic consequences to those observed 
in IUGR-born animals (Yates et al., 2011; 2012) 
(Figure 2). Collectively, these results indicate that 
mTORC1 is a key mediator of the effects of β2 stim-
ulation that we have observed on both basal and 
insulin-stimulated glucose oxidation in skeletal 
muscle and myoblasts (Cadaret et al., 2017; Merrick 
et al., 2017). More importantly, they also indicate 
a potential key role for mTORC1 in the metabolic 
phenotype associated with IUGR-induced adapta-
tions. Indeed, these mTORC1-mediated pathways 
not only provide a mechanistic model for the role 
of the β2 adrenergic system in regulation of glucose 
homeostasis but may also represent a potential 
target for improving metabolic outcomes in IUGR-
born individuals.
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CONCLUSIONS
Skeletal muscle glucose oxidation is a major factor 
in glucose homeostasis and metabolic health. In 
this review, we describe key roles for mTORC1 and 
mTORC2 in β2 adrenergic pathways that appear 
to regulate skeletal muscle glucose oxidation rates 
and capacity. Research has shown that adrenergic 
adaptations appear to be highly involved in glucose 
oxidation deficits in IUGR skeletal muscle and 
thus these pathways represent potential therapeu-
tic targets for metabolic disorders associated with 
IUGR. We recently observed that β2 adrenergic 
activity enhances both insulin-stimulated and 
insulin-independent glucose oxidation in skeletal 
muscle and myoblasts without parallel effects on 
glucose uptake. We postulate that this is explained 
by two parallel β2 adrenergic pathways for Rheb 
activation, one involving mTORC2-mediated 
activation of Akt and the other resulting from 
cAMP-mediated inhibition of the Rheb suppres-
sor, PDE4B. Strikingly similar metabolic deficien-
cies between IUGR animal models and mTORC1 
knockout models make these separate but compli-
mentary pathways for β2 adrenergic enhancement 
of Rheb-mediated mTORC1 activity particularly 
intriguing as potential therapeutic targets for 
IUGR-induced metabolic dysfunction. 
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